The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Open accessAbstract
SYNOPSIS Glucocorticoid administration is the most common cause of secondary osteoporosis and the leading cause of nontraumatic osteonecrosis. In patients receiving long-term therapy, glucocorticoids induce fractures in 30 to 50% and osteonecrosis in 9 to 40%. This article reviews glucocorticoid-induced osteoporosis and osteonecrosis addressing the risk factors, pathogenesis, evaluation, treatment, and uncertainties in the clinical management of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
Seeman, E., & Delmas, P. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra053077 · Cited by 2,080
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 3×
“Inadequate numbers of osteoblasts and incomplete erosion cavity repair during bone remodeling are the main cause of the reduction in cancellous bone area, wall width, trabecular width and bone formation rate typically found in GIO (22).”
BackgroundSelf-citationKhosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Self-citationAlendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Nontraumatic Necrosis of Bone (Osteonecrosis)
Desforges, J. F., & Mankin, H. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262206 · Cited by 958
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“In addition, alendronate decreases glucocorticoid-induced osteocyte apoptosis (46), which may play a role in the preservation of bone strength (25).”
BackgroundSelf-citationCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Self-citationGlucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Self-citationReid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 592
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 512
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464
Glucocorticoid-induced osteonecrosis
Weinstein, R. S. (2012) · Endocrine · doi:10.1007/s12020-011-9580-0 · Cited by 428
Self-citationInhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR?2
Lecka-Czernik, B., Gubrij, I., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990901)74:3<357::aid-jcb5>3.0.co;2-7 · Cited by 405
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Jia, D., O’Brien, C. A., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2006) · Endocrinology · doi:10.1210/en.2006-0459 · Cited by 394
Self-citationGiant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Self-citationBone loss in response to long-term glucocorticoid therapy
LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., & DellaRocca, C. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90139-q · Cited by 384
Apoptosis of Osteocytes in Glucocorticoid-Induced Osteonecrosis of the Hip1
Weinstein, R. S., Nicholas, R. W., & Manolagas, S. C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6714 · Cited by 378
Self-citationAngeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 365
Zhao, D., Cui, D., Wang, B., Tian, F., Guo, L., Yang, L., Liu, B., & Yu, X. (2012) · Bone · doi:10.1016/j.bone.2011.11.002 · Cited by 360
Lai, K.-A. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02959 · Cited by 332
Weinstein, R. S., Chen, J.-R., Powers, C. C., Stewart, S. A., Landes, R. D., Bellido, T., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214538 · Cited by 313
Self-citationApoptosis of Osteocytes in Glucocorticoid-Induced Osteonecrosis of the Hip
Weinstein, R. S. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2907 · Cited by 313
Self-citationFracture risk with intermittent high‐dose oral glucocorticoid therapy
De Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C., & Van Staa, T. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 298
Oral glucocorticoid use is associated with an increased risk of fracture
Steinbuch, M., Youket, T. E., & Cohen, S. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1548-3 · Cited by 277
Weinstein, R. S., Wan, C., Liu, Q., Wang, Y., Almeida, M., O’Brien, C. A., Thostenson, J., Roberson, P. K., Boskey, A. L., Clemens, T. L., et al. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00545.x · Cited by 276
Self-citationAlmeida, M., Han, L., Ambrogini, E., Weinstein, R. S., & Manolagas, S. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.283481 · Cited by 270
Self-citationCooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
Russcher, H., Smit, P., van den Akker, E. L. T., van Rossum, E. F. C., Brinkmann, A. O., de Jong, F. H., Lamberts, S. W. J., & Koper, J. W. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0646 · Cited by 199
Ohnaka, K., Taniguchi, H., Kawate, H., Nawata, H., & Takayanagi, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.025 · Cited by 198
Dore, R. K., Cohen, S. B., Lane, N. E., Palmer, W., Shergy, W., Zhou, L., Wang, H., Tsuji, W., & Newmark, R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.112920 · Cited by 194
Rubin, M. R., & Bilezikian, J. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-012101 · Cited by 193
Corticosteroid-Induced Bone Loss in Men
Pearce, G. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.801 · Cited by 184
Skversky, A. L., Kumar, J., Abramowitz, M. K., Kaskel, F. J., & Melamed, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1600 · Cited by 163
MAJOR UNDESIRABLE SIDE-EFFECTS RESULTING FROM PREDNISOLONE AND PREDNISONE
Bollet, A. J. (1955) · Journal of the American Medical Association · doi:10.1001/jama.1955.02960060017005 · Cited by 160
Tauchmanovà, L., Pivonello, R., Somma, C. D., Rossi, R., Martino, M. C. D., Camera, L., Klain, M., Salvatore, M., Lombardi, G., & Colao, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0582 · Cited by 155
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patients
Curtis, J. R., Westfall, A. O., Allison, J. J., Becker, A., Casebeer, L. L., Freeman, A. N., Spettell, C. M., Weissman, N., Wilke, S., & Saag, K. G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21194 · Cited by 153
Weinstein, R. S., Jilka, R. L., Almeida, M., Roberson, P. K., & Manolagas, S. C. (2010) · Endocrinology · doi:10.1210/en.2009-1488 · Cited by 116
Self-citationMedical Malpractice and Corticosteroid Use
Nash, J. J., Nash, A. G., Leach, M. E., & Poetker, D. M. (2010) · Otolaryngology · doi:10.1177/0194599810390470 · Cited by 89
The Skeletal Effects of Glucocorticoid Excess Override Those of Orchidectomy in Mice
Weinstein, R. S., Jia, D., Powers, C. C., Stewart, S. A., Jilka, R. L., PARFITT, A. M., & Manolagas, S. C. (2004) · Endocrinology · doi:10.1210/en.2003-1133 · Cited by 86
Self-citationUncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
MANAGEMENT OF RHEUMATOID ARTHRITIS WITH SMALLER (MAINTENANCE) DOSES OF CORTISONE ACETATE
Boland, E. W. (1950) · JAMA · doi:10.1001/jama.1950.02920050005002 · Cited by 63
Safety of parathyroid hormone for the treatment of osteoporosis
Miller, P. D. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0003-y · Cited by 60
Devogelaer, J., Adler, R. A., Recknor, C. P., See, K., Warner, M. R., Wong, M., & Krohn, K. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090411 · Cited by 59
Tatsuno, I., Sugiyama, T., Suzuki, S., Yoshida, T., Tanaka, T., Sueishi, M., & Saitō, Y. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1578 · Cited by 50
Poetker, D. M., & Smith, T. L. (2012) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21016 · Cited by 49
Emkey, R. D., Delmas, P. D., Goemaere, S., Liberman, U. A., Poubelle, P. E., Daifotis, A. G., Verbruggen, N., Lombardi, A., & Czachur, M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10861 · Cited by 47
Osteoprotegerin Prevents Glucocorticoid-Induced Osteocyte Apoptosis in Mice
Weinstein, R. S., O’Brien, C. A., Almeida, M., Zhao, H., Roberson, P. K., Jilka, R. L., & Manolagas, S. C. (2011) · Endocrinology · doi:10.1210/en.2011-0170 · Cited by 44
Self-citationSymptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis.
Syed, M. I., Patel, N. A., Jan, S., Shaikh, A., Grunden, B. K., & Morar, K. (2006) · PubMed Central · Cited by 38
Thompson, J. M., Modin, G. W., Arnaud, C. D., & Lane, N. E. (1997) · Calcified Tissue International · doi:10.1007/s002239900351 · Cited by 27
Weinstein, R. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0372 · Cited by 23
Self-citationWarrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2
Cited by
Long-term side effects of glucocorticoids
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1140743 · Cited by 869
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
The Key Role of the Blood Supply to Bone
Marenzana, M., & Arnett, T. R. (2013) · Bone Research · doi:10.4248/br201303001 · Cited by 366
Strehl, C., Bijlsma, J. W. J., de Wit, M., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 340
Guidelines for the management of osteoporosis and fragility fractures
Nuti, R., Brandi, M. L., Checchia, G., Di Munno, O., Dominguez, L., Falaschi, P., Fiore, C. E., Iolascon, G., Maggi, S., Michieli, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1874-2 · Cited by 328
Metadata
- Authors
- Weinstein, R. S.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 41
- Issue
- 3
- Pages
- 595-611
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W2020229324
- Cited by
- 364
- References
- 62
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.